New pill may cut blood transfusions for kids with thalassemia
NCT ID NCT07506863
First seen Jun 27, 2026 · Last updated Aug 04, 2026 · Updated 2 times
Summary
This study tests a drug called mitapivat in children aged 1 to 17 with alpha- or beta-thalassemia who need regular blood transfusions. The goal is to see if mitapivat can reduce the number of transfusions needed compared to a placebo. The study involves 54 participants and lasts about 48 weeks.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRANSFUSION-DEPENDENT ALPHA-THALASSEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
University of Texas Southwestern Medical Center
RECRUITINGDallas, Texas, 75390, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Gene therapy aims to free Beta-Thalassemia patients from lifelong transfusions
- Can metformin or hydroxyurea cut transfusions for thalassemia patients?
- New stem cell transplant trial aims to treat sickle cell disease and other blood disorders
- Weekly shot could replace daily insulin for thalassemia kids with diabetes
- New blood storage method could mean fewer transfusions for thalassemia patients
- Could two old drugs free thalassemia patients from lifelong transfusions?